15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $36M | -$6M | 33.8% | -17.2% | -$6M | — | $9M |
| 2024 | $35M | -$5M | 30.6% | -16.7% | -$14M | — | $10M |
| 2023 | $24M | -$5M | 34.6% | -19.9% | -$9M | — | $16M |
| 2022 | $4M | -$27M | 39.0% | -621.3% | -$5M | — | $22M |
| 2021 | $228426 | -$12M | 48.4% | -1068.2% | -$2M | — | $2M |
| 2020 | $71410 | -$3M | 63.8% | -807.8% | -$658490 | $949006 | $989888 |
| 2019 | $21121 | -$2M | 47.7% | -3037.9% | -$496658 | — | $40501 |
| 2018 | $0 | -$2M | — | — | -$531656 | — | — |
| 2017 | $0 | -$1M | — | — | -$547238 | — | — |
| 2016 | — | -$3M | — | — | -$317621 | — | — |
| 2015 | — | -$2M | — | — | -$872437 | — | — |
| 2014 | — | -$2M | — | — | -$538595 | — | — |
| 2014 | — | -$6M | — | — | — | — | — |
| 2013 | — | -$2M | — | — | — | — | — |
| 2013 | — | -$5M | — | — | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $8M | -$1M | 27.0% | -17.3% | -$2M | — | $7M |
| Dec '25 | $9M | -$2M | 35.3% | -20.9% | -$2M | — | $9M |
| Sep '25 | $9M | -$883820 | 32.6% | -11.5% | -$735840 | — | $9M |
| Jun '25 | $9M | -$2M | 36.4% | -21.8% | -$1M | — | $10M |
| Mar '25 | $9M | -$1M | 30.7% | -14.6% | -$2M | — | $8M |
| Dec '24 | $10M | -$2M | 32.2% | -21.2% | -$4M | — | $10M |
| Sep '24 | $8M | -$1M | 34.0% | -13.1% | -$2M | — | $12M |
| Jun '24 | $9M | -$494300 | 25.3% | -13.6% | -$6M | — | $12M |
| Mar '24 | $8M | -$1M | 31.2% | -17.9% | -$3M | — | $17M |
| Dec '23 | $8M | -$1M | 33.4% | -15.5% | -$2M | — | $16M |
| Sep '23 | $6M | -$651482 | 33.4% | -13.1% | -$466923 | — | $19M |
| Jun '23 | $6M | -$902108 | 35.1% | -18.2% | — | — | $20M |
| Mar '23 | $5M | -$2M | 37.4% | -37.4% | — | — | $19M |
| Dec '22 | $4M | -$24M | 37.8% | -593.0% | -$2M | — | $22M |
| Sep '22 | $132808 | -$1M | 50.5% | -1293.6% | -$1M | — | $41M |
| Jun '22 | $150307 | -$538872 | 50.3% | -462.9% | — | — | $42M |
| Mar '22 | $122645 | -$1M | 51.2% | -997.5% | — | — | $13M |
| Dec '21 | $85118 | $667116 | 28.0% | -328.5% | -$312113 | — | $2M |
| Sep '21 | $50376 | -$4M | 61.3% | -985.1% | — | — | $2M |
| Jun '21 | $52874 | -$3M | 65.0% | -735.0% | — | $2M | $2M |
How the market has priced SBFM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Sunshine Biopharma Inc.'s revenue has grown 247.7% per year. These are computed facts, not advice.
As of FY2025, Sunshine Biopharma Inc. reported — of total debt against $9M of cash.
In FY2025, gross margin was 33.8%, operating margin -17.2%, and net margin -16.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.